Market research
WAVE.V Waverley Pharma Inc
V CAD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 540K
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 1.46
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA94357L1058
- Market cap
- 540K
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 1.46
About
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Research context
Waverley Pharma Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the WAVE.V discussion.
5 years, 6 months ago
Waverley Pharma Inc is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Waverley Pharma Inc's total revenue rose by 33.7% to $353K since the same quarter in the previous year.
Its net income has increased by 100.2% to $989 since the same quarter in the previous year.
Finally, its free cash flow grew by 129.3% to $179K since the same quarter in the previous year.
Based on the above factors, Waverley Pharma Inc gets an overall score of 4/5.